Comparative effects of left bundle branch area pacing, His bundle pacing, biventricular pacing in patients requiring

Juan Hua1, Chenxi Wang1, Qiling Kong1

  • 1Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Clinical Cardiology
|February 7, 2022
PubMed

Insights

Left bundle branch area pacing (LBBAP) and His bundle pacing (HBP) improve cardiac function more than biventricular pacing (BVP) for cardiac resynchronization therapy (CRT). LBBAP offers similar benefits to HBP but with lower pacing thresholds.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Comparative efficacy of different cardiac resynchronization therapy (CRT) pacing methods, including biventricular pacing (BVP), His bundle pacing (HBP), and left bundle branch area pacing (LBBAP), is not well-established.
  • HBP and LBBAP show potential advantages over traditional BVP for CRT.

Purpose of the Study:

  • To systematically compare the effects of BVP, HBP, and LBBAP on CRT outcomes.
  • To determine if HBP or LBBAP offer superior results compared to BVP.

Main Methods:

  • A systematic literature search was conducted across PubMed, Embase, Web of Science, and Cochrane Library.
  • A frequentist random-effects network meta-analysis (NMA) was employed to compare outcomes between the pacing groups.
  • Mean differences (MDs) and 95% confidence intervals (CIs) were calculated to assess treatment effects.

Main Results:

  • The meta-analysis included 6 studies with 389 patients, with a mean follow-up of 8.03 months.
  • LBBAP demonstrated the greatest improvement in left ventricular ejection fraction (LVEF%), followed by HBP, compared to BVP.
  • Both HBP and LBBAP significantly narrowed QRS duration compared to BVP, with LBBAP showing a lower pacing threshold than both BVP and HBP.

Conclusions:

  • LBBAP and HBP significantly enhance LVEF and reduce QRS duration more effectively than BVP for CRT.
  • LBBAP provides comparable clinical outcomes to HBP but with the advantage of lower pacing thresholds, suggesting it may be a preferred option for CRT.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
460
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
51
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
56
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
782
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
79